Cognition Therapeutics CEO issues letter to shareholders

Cognition Therapeutics announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. “The year ahead holds great promise for Cognition Therapeutics. We are anticipating proof-of-concept data from two Phase 2 neurodegenerative disease studies of our lead clinical oral product candidate, CT1812: the SHINE trial in mild-to-moderate Alzheimer’s disease and the SHIMMER trial in mild-to-moderate dementia with Lewy bodies. As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community. With the landmark approval of the first disease-modifying anti-amyloid drugs, patients and their families can access treatments to slow the progression of Alzheimer’s disease… Advances are continuing not only in disease treatment but in the development of tools for diagnosis and monitoring. Results from our studies with fluid biomarkers and instruments like quantitative EEG, as well as those of other innovating companies using these tools, are providing insights into noninvasive ways to diagnose, stage and monitor treatments… Key Clinical Milestones Expected in 2024. Our first catalyst in 2024 is expected to occur at mid-year when we unblind topline safety and efficacy data from our Phase 2 SHINE trial of oral CT1812 in adults with mild-to-moderate Alzheimer’s disease… Also in 2024, we anticipate reaching full enrollment for our SHIMMER trial, which is evaluating oral CT1812 in adults diagnosed with mild-to-moderate DLB, the second most common form of dementia. More than half of DLB patients are estimated to have both Abeta and alpha-synuclein oligomers in the brain.. Our 540-patient START trial in adults with early Alzheimer’s disease is actively recruiting participants from a number of Alzheimer’s Clinical Trials Consortium centers of excellence. We and our collaborators on this study made the important decision to allow participants on stable background therapy with lecanemab to enroll in START, which we expect will provide real-world evidence of CT1812’s potential as a monotherapy and in combination with monoclonal antibody treatments. In addition, our early proteomics analyses and subsequent preclinical work provided compelling evidence that the sigma-2 receptor has an important role in the function of retinal pigment epithelial cells,”